ITT Allowance for Doubtful Accounts Receivable (Current) increased by 13.0% to $20.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 49.3%, from $14.00M to $20.90M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 4.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.80M | $11.50M | $12.00M | $15.40M | $16.40M | $12.90M | $11.70M | $12.60M | $15.60M | $14.30M | $14.20M | $14.90M | $14.10M | $16.50M | $14.20M | $14.00M | $15.50M | $18.70M | $18.50M | $20.90M |
| QoQ Change | — | -10.2% | +4.3% | +28.3% | +6.5% | -21.3% | -9.3% | +7.7% | +23.8% | -8.3% | -0.7% | +4.9% | -5.4% | +17.0% | -13.9% | -1.4% | +10.7% | +20.6% | -1.1% | +13.0% |
| YoY Change | — | — | — | — | +28.1% | +12.2% | -2.5% | -18.2% | -4.9% | +10.9% | +21.4% | +18.3% | -9.6% | +15.4% | +0.0% | -6.0% | +9.9% | +13.3% | +30.3% | +49.3% |